Celldex director granted options on 26,000 shares

Celldex Therapeutics director Neil Garry Arthur received a compensation-related stock option grant.

Rhea-AI Filing Summary

Celldex Therapeutics director Neil Garry Arthur received a compensation-related stock option grant. He was awarded non-qualified options to acquire 26,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan. These options become exercisable starting on June 25, 2027 and expire on June 25, 2036, and this grant represents the full 26,000 derivative shares reported as held following the transaction.

Insider Trade Summary

Grant/Award: 26,000 shares

Grant/Award 1 txn

Insider NEIL GARRY ARTHUR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct)

Footnotes (1)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Key Figures

Option grant size: 26,000 shares Exercise price: $34.09 per share Total derivative holdings: 26,000 shares +2 more

5 metrics

Option grant size 26,000 shares Non-qualified stock options granted to director

Exercise price $34.09 per share Strike price for the 26,000 options

Total derivative holdings 26,000 shares Derivative shares following the transaction

Option exercisability date June 25, 2027 Date options first become exercisable

Option expiration date June 25, 2036 Final expiration of the option grant

Key Terms

Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, Grant, award, or other acquisition, derivative transaction

4 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

2021 Omnibus Equity Incentive Plan financial

"option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative transaction financial

"derivativeTransactionCount: 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex Therapeutics (CLDX) director Neil Garry Arthur report in this Form 4?

Neil Garry Arthur reported receiving a non-qualified stock option grant for 26,000 shares of Celldex common stock. The options were granted as compensation under the 2021 Omnibus Equity Incentive Plan at a fixed exercise price.

How many Celldex (CLDX) shares are covered by Neil Garry Arthur’s new options?

The grant covers options to purchase 26,000 shares of Celldex common stock. This entire 26,000-share option position is shown as the total derivative holdings following the reported transaction in the Form 4 filing.

What is the exercise price of Neil Garry Arthur’s Celldex (CLDX) stock options?

The options have an exercise price of $34.09 per share. This means Arthur can acquire Celldex common stock at $34.09 per share once the options become exercisable according to the grant’s vesting terms.

When do Neil Garry Arthur’s Celldex (CLDX) options vest and expire?

The options become exercisable starting June 25, 2027, and expire on June 25, 2036. After the expiration date, any unexercised options from this 26,000-share grant will no longer be usable.

Were Neil Garry Arthur’s Celldex (CLDX) options granted under a specific equity plan?

Yes. The Form 4 states the options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan governs equity-based compensation awards such as stock options for eligible participants at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEIL GARRY ARTHUR

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 202

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for Garry A. Neil, M.D.	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)